Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Detalles Bibliográficos
Autores principales: Concordet, D., Gandia, P., Montastruc, J. L., Bousquet-Mélou, A., Lees, P., Ferran, A. A., Toutain, P. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007435/
https://www.ncbi.nlm.nih.gov/pubmed/31802401
http://dx.doi.org/10.1007/s40262-019-00848-z
_version_ 1783495318215589888
author Concordet, D.
Gandia, P.
Montastruc, J. L.
Bousquet-Mélou, A.
Lees, P.
Ferran, A. A.
Toutain, P. L.
author_facet Concordet, D.
Gandia, P.
Montastruc, J. L.
Bousquet-Mélou, A.
Lees, P.
Ferran, A. A.
Toutain, P. L.
author_sort Concordet, D.
collection PubMed
description
format Online
Article
Text
id pubmed-7007435
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-70074352020-02-24 Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?” Concordet, D. Gandia, P. Montastruc, J. L. Bousquet-Mélou, A. Lees, P. Ferran, A. A. Toutain, P. L. Clin Pharmacokinet Letter to the Editor Springer International Publishing 2019-12-05 2020 /pmc/articles/PMC7007435/ /pubmed/31802401 http://dx.doi.org/10.1007/s40262-019-00848-z Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Concordet, D.
Gandia, P.
Montastruc, J. L.
Bousquet-Mélou, A.
Lees, P.
Ferran, A. A.
Toutain, P. L.
Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_full Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_fullStr Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_full_unstemmed Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_short Authors’ Reply to Krebs-Brown et al. Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_sort authors’ reply to krebs-brown et al. comment on: “why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one?”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007435/
https://www.ncbi.nlm.nih.gov/pubmed/31802401
http://dx.doi.org/10.1007/s40262-019-00848-z
work_keys_str_mv AT concordetd authorsreplytokrebsbrownetalcommentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT gandiap authorsreplytokrebsbrownetalcommentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT montastrucjl authorsreplytokrebsbrownetalcommentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT bousquetmeloua authorsreplytokrebsbrownetalcommentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT leesp authorsreplytokrebsbrownetalcommentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT ferranaa authorsreplytokrebsbrownetalcommentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT toutainpl authorsreplytokrebsbrownetalcommentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone

Ejemplares similares